Overview
- Under the agreement Innovent will receive a $650 million upfront payment and can earn up to $9.85 billion in milestones plus up to double‑digit royalties if products are approved.
- The collaboration covers R&D on 12 early‑stage and de novo antibody‑drug conjugates and establishes four global programs whose development costs will be shared by the partners.
- Pfizer and Innovent will co‑commercialize approved products in the U.S. and Europe and split profits, while Innovent keeps exclusive commercialization rights for Greater China.
- The transaction has been publicly announced but remains subject to unspecified regulatory approvals that must clear before closing.
- Analysts say the deal reflects a wider pharma trend of licensing to refill oncology pipelines ahead of an expected patent cliff and could speed patient access if the ADCs prove safe and effective.